stoxline Quote Chart Rank Option Currency Glossary
  
Liquidia Corporation (LQDA)
15.75  -0.21 (-1.32%)    02-07 19:43
Open: 16.01
High: 16.02
Volume: 808,558
  
Pre. Close: 15.96
Low: 15.38
Market Cap: 1,333(M)
Technical analysis
2025-02-07 4:45:44 PM
Short term     
Mid term     
Targets 6-month :  18.89 1-year :  22.07
Resists First :  16.18 Second :  18.89
Pivot price 14.48
Supports First :  13.18 Second :  11.34
MAs MA(5) :  15.38 MA(20) :  13.86
MA(100) :  11.48 MA(250) :  12.3
MACD MACD :  0.9 Signal :  0.8
%K %D K(14,3) :  94.4 D(3) :  95.3
RSI RSI(14): 75.6
52-week High :  16.98 Low :  8.26
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LQDA ] has closed below upper band by 10.9%. Bollinger Bands are 77.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 12 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 16.03 - 16.11 16.11 - 16.17
Low: 15.19 - 15.3 15.3 - 15.36
Close: 15.6 - 15.76 15.76 - 15.86
Company Description

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Headline News

Sat, 08 Feb 2025
Liquidia Corp's chief business officer sells $6,319 in stock - MSN

Sat, 08 Feb 2025
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc.(LQDA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Fri, 07 Feb 2025
(LQDA) Investment Report - Stock Traders Daily

Thu, 06 Feb 2025
Liquidia Corp.: We Have Exposure To The Upside Now - Seeking Alpha

Fri, 31 Jan 2025
Liquidia Corporation's Long-Running Saga Is Coming To An End (NASDAQ:LQDA) - Seeking Alpha

Wed, 22 Jan 2025
Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 85 (M)
Shares Float 48 (M)
Held by Insiders 19.4 (%)
Held by Institutions 54.3 (%)
Shares Short 10,330 (K)
Shares Short P.Month 11,840 (K)
Stock Financials
EPS -1.63
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.68
Profit Margin 0 %
Operating Margin -743.3 %
Return on Assets (ttm) -40.7 %
Return on Equity (ttm) -181.8 %
Qtrly Rev. Growth -23.5 %
Gross Profit (p.s.) 0.12
Sales Per Share 0.17
EBITDA (p.s.) -1.14
Qtrly Earnings Growth 0 %
Operating Cash Flow -75 (M)
Levered Free Cash Flow -70 (M)
Stock Valuations
PE Ratio -9.73
PEG Ratio 0
Price to Book value 22.82
Price to Sales 89.83
Price to Cash Flow -17.76
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android